title: Plasmablastic multiple myeloma following clear cell renal cell carcinoma.
abstract: We aim to describe the clinicohaematological profile of an elderly male with plasmablastic multiple myeloma (MM) (IgG λ, International System Stage II) with an unfavourable outcome following chemotherapy. The serum interleukin-6 level was found to be markedly elevated (2464 pg/mL, reference; <50 pg/mL). Thirty-six months prior to MM diagnosis, he underwent left radical nephrectomy for a stage III (pT3N0M0) clear cell renal cell carcinoma (RCC, Fuhrman grade 2). The unique MM-RCC association, shared risk factors, myeloma pathobiology and clinical implications are discussed with a brief literature review.
authors.affiliation: Department of Pathology, Pondicherry Institute of Medical Sciences, Pondicherry, India.
authors.forename: Somanath
authors.initials: S
authors.lastname: Padhi
authors.affiliation: Department of General Medicine, Pondicherry Institute of Medical Sciences, Pondicherry, India.
authors.forename: Sudhagar
authors.initials: S
authors.lastname: Mokkappan
authors.affiliation: Department of Pathology, Pondicherry Institute of Medical Sciences, Pondicherry, India.
authors.forename: Renu G' Boy
authors.initials: RG
authors.lastname: Varghese
authors.affiliation: Department of Nephrology, Pondicherry Institute of Medical Sciences, Pondicherry, India.
authors.forename: Ilangovan
authors.initials: I
authors.lastname: Veerappan
mesh_terms: D002292:Carcinoma, Renal Cell / Q000097:blood / Q000150:complications / Q000601:surgery; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D007668:Kidney / Q000473:pathology*; D007680:Kidney Neoplasms / Q000097:blood / Q000150:complications / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D009392:Nephrectomy; D010950:Plasma Cells / Q000473:pathology*; D011183:Postoperative Complications; D012307:Risk Factors
chemical_list: D015850:Interleukin-6
references.citation: Indian J Med Paediatr Oncol. 2013 Oct;34(4):283-91
references.pmid: 24604959
references.citation: Clin Lymphoma Myeloma. 2008 Jun;8(3):188-90
references.pmid: 18650185
references.citation: J BUON. 2009 Jul-Sep;14(3):511-4
references.pmid: 19810147
references.citation: BJU Int. 2011 Sep;108(6):825-30
references.pmid: 21091979
references.citation: Eur J Haematol. 2009 Apr;82(4):277-87
references.pmid: 19187270
references.citation: BJU Int. 2008 Mar;101(6):712-5
references.pmid: 17970789
references.citation: Leuk Lymphoma. 2007 Aug;48(8):1662-4
references.pmid: 17701606
references.citation: N Engl J Med. 1991 Jun 27;324(26):1893-4
references.pmid: 2041555
references.citation: BJU Int. 2006 Apr;97(4):698-702
references.pmid: 16536756
references.citation: Diagn Cytopathol. 1993 Oct;9(5):551-4
references.pmid: 8287765
references.citation: N Engl J Med. 2011 Mar 17;364(11):1046-60
references.pmid: 21410373